ELN : Analysis & Opinions

  1. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  2. The Top 10 Financial Tweets For Monday, July 29

    July 29, 2013
    There are millions of tweets written every day. Benzinga sifts through the maelstrom of information to find the ten best ...
  3. Benzinga Market Primer: Monday, July 29: Futures Lower On Chinese ...

    July 29, 2013
    Futures Lower On Chinese FearsU.S. equity futures traded slightly lower in early pre-market trade after Asian shares on fears ...
  4. PDL BioPharma Guides Higher 2Q Royalties - Analyst Blog

    June 13, 2013
    PDL BioPharma announced that it expects to receive second quarter 2013 royalty revenues of around $143 million.
  5. Spectrum Acquires Apaziquone Rights - Analyst Blog

    February 4, 2013
    Spectrum Pharmaceuticals (SPPI) recently announced that it has regained development and commercial rights for apaziquone ...
  6. Earnings Miss for Biogen - Analyst Blog

    January 28, 2013
    Biogen Idec (BIIB) reported fourth quarter earnings per share of $1.40, missing the Zacks Consensus Estimate of $1.46 and ...
  7. Lilly Plans Trial for Solanezumab - Analyst Blog

    December 13, 2012
    Eli Lilly (LLY) recently provided an update on its plans for its Alzheimer's disease candidate, solanezumab. The company ...
  8. PDLI Guides Q4 Royalty Rev to $86M - Analyst Blog

    December 7, 2012
    PDL BioPharma Inc. (PDLI) recently announced that it expects to generate fourth quarter 2012 royalty revenues of $86 million, ...
  9. Elan Starts Phase II AD Study - Analyst Blog

    November 28, 2012
    Elan Corporation (ELN) recently initiated a phase II study on ELND005 (Study AG201) for the treatment of agitation/aggression ...
  10. PDLI's EPS In Line, Revenue Misses - Analyst Blog

    November 7, 2012
    PDL BioPharma Inc. (PDLI) posted third-quarter earnings of 32 cents per share, in line with the Zacks Consensus Estimate ...
  11. Biogen Beats, Raises View Again - Analyst Blog

    October 25, 2012
    Biogen Idec (BIIB) reported third quarter earnings per share of $1.90, well above the Zacks Consensus Estimate of $1.61 and ...
  12. PDLI-AxoGen Complete Financing Deal - Analyst Blog

    October 10, 2012
    PDL BioPharma, Inc. (PDLI) and AxoGen, Inc. (AXGN) recently completed a structured financing transaction. As per the financing ...
  13. Lilly Up on Alzheimer's Data - Analyst Blog

    October 9, 2012
    Shares of Eli Lilly and Company (LLY) reached a 52-week high of $50.94 on Monday with the company reporting full results ...
  14. PDLI Guides Q3 Royalty Rev to $85M - Analyst Blog

    September 7, 2012
    PDL BioPharma Inc. (PDLI) recently announced that it expects to generate third quarter 2012 royalty revenues of $85 million, ...
  15. Celgene and Other Big Movers In Healthcare on August 30, 2012

    August 30, 2012
    The market is currently down, with the Nasdaq slipping 0.9%, the S&P 500 down 0.7% and the Dow declining 0.7%. The healthcare ...
  16. Lilly's Alzheimer's Candidate Fails - Analyst Blog

    August 28, 2012
    Eli Lilly and Company (LLY) recently announced much awaited top-line results on Alzheimer's disease candidate, solanezumab ...
  17. Big Movers on the Healthcare Sector Today, Including VRX

    August 7, 2012
    The market is having a good day so far: the Nasdaq has climbed 0.8%; the S&P 500 is up 0.7%; and the Dow has risen 0.6%. ...
  18. PDL BioPharma Beats Zacks Estimates - Analyst Blog

    August 6, 2012
    PDL BioPharma Inc. (PDLI) posted second-quarter earnings of 53 cents per share, above the year-ago figure of 39 cents and ...
  19. Solid Quarter at ALKS, View Backed - Analyst Blog

    July 31, 2012
    Alkermes plc (ALKS) reported earnings of 28 cents per share (including depreciation and stock-based compensation expenses) ...
  20. Pfizer, J&J Drug Fails in 1st Study - Analyst Blog

    July 24, 2012
    Pfizer, Inc. (PFE) recently announced highly-awaited top-line results on Alzheimer's disease candidate, bapineuzumab. Pfizer ...
  21. Biogen Beats on All Fronts - Analyst Blog

    July 24, 2012
    Biogen Idec (BIIB) reported second quarter earnings per share of $1.82, well above the Zacks Consensus Estimate of $1.56 ...
  22. PDL BioPharma Guides Q2 Royalty Rev to $125M - Analyst Blog

    June 14, 2012
    PDL BioPharma Inc. (PDLI) recently announced that it expects to generate second-quarter 2012 royalty revenues of $125 million, ...
  23. Earnings Beat at PDL BioPharma - Analyst Blog

    May 8, 2012
    PDL BioPharma Inc. (PDLI) posted first quarter earnings of 30 cents per share, above the year-ago figure of 25 cents and ...
  24. The War Against Alzheimer's Requires Thinking Small

    January 2, 2012
    A meaningful treatment for Alzheimer's is no longer out of reach. Find out which companies are in the race to find a cure.
  25. Biogen Idec Has Built A Valuable Franchise

    November 1, 2011
    Biogen Idec is a go-to name in MS that carries a lot of value. A credible buy for those with longer horizons.
  26. Teva's Rocky Road

    April 26, 2011
    Teva's stock has taken a beating, but the next five years are likely to be tough.
  27. Tepid Teva Somewhat Tempting

    February 9, 2011
    Teva's results and outlook will likely leave the stock cooling its heels for a bit in this growth-obsessed market, but patient ...
  28. Weak Dollar And Low Valuation To Boost J&J

    October 15, 2009
    A couple of key investment merits should eventually allow J&J’s share price to increase markedly.
Investing News
  1. Outside the Box: Hoisington Investment Management Quarterly Review and Outlook, First ...

    Outside the Box: Hoisington Investment Management Quarterly Review and Outlook, First Quarter ...
  2. Why Stick With Energy Stocks? (Hint: Geopolitical Risk)

    By most fundamental measures, oil prices should be declining. Russ explains why they’re on ...
  3. Bad Investor Behavior: Overemphasizing Experience

    Behavioral finance researchers have discovered that our personal experiences disproportionately ...
  4. Thoughts From The Frontline: Every Central Bank For Itself

    Thoughts from the Frontline: Every Central Bank for Itself
  5. 3 Dumb Ways to Borrow Money

    Money — everyone needs it, but not everyone has it. Many people who find themselves in a ...
  6. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
Trading Center